Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Insight Molecular Diagnostics Inc.
| Metric | Insight Molecular Diagnostics Inc. IMDXHealthcare |
|---|---|
| Quality Score | 56 / 100 |
| Revenue (latest) | $4M |
| Net income (latest) | −$50M |
| Operating margin | −1260.8% |
| Net margin | −1238.5% |
| Return on equity | 159.6% |
| Return on assets | −195.0% |
| Return on capital (ROCE) | −373.7% |
| Debt / equity | — |
| Revenue growth (YoY) | 115.6% |
| Altman Z″ (distress) | -63.82 |
| Accruals / assets | −108.9% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.